Maven Securities’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Maven Securities’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-62,500	Closed	-$101K	–	1151
2021 Q3	$101K	Hold	62,500	–	–	﹤0.01%	993
2021 Q2	$109K	Hold	62,500	–	–	﹤0.01%	966
2021 Q1	$84K	Hold	62,500	–	–	﹤0.01%	1026
2020 Q4	$128K	Buy	+62,500	New	+$108K	0.01%	523

Other funds holding STLNW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

USPCM

Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Maven Securities's STLNW Position: Q4 2021 in Review

Maven Securities sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2021, closing a stake of 62,500 shares — an estimated $101K sold.

Maven Securities first reported a position in STLNW in Q4 2020 and held it in 4 quarters. The position peaked at $128K in Q4 2020. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

Maven Securities reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
Maven Securities sold 62,500 Starling Oncology, Inc. Warrant shares in Q4 2021, an estimated $101K.
Maven Securities first reported a position in Starling Oncology, Inc. Warrant in Q4 2020 and held it in 4 quarters.
Maven Securities's Starling Oncology, Inc. Warrant position peaked at $128K in Q4 2020.
20 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2021.

Based on Maven Securities's 13F filing for Q4 2021, filed 14 Feb 2022.